Hereditary Angioedema Market to Witness Robust Growth as BioCryst Pharmaceuticals, Inc. Receives the U.S. FDA Approval for its ORLADEYO indicated for hereditary angioedema

 

Hereditary Angioedema is a disease, which is the result of genetic mutation, within the families with higher genetic activity. It is not contagious to others. The cause of heredity is still unknown but it is believed that the disease is related to the immunological mechanism. Hereditary Angioedema is a chronic non-inflammatory disease that affects millions of people around the world. Symptoms include persistent dryness of the skin, scalp itching, inflammation, rash, severe skin peeling and cracking, bleeding and hives, pain in the area where the skin is affected. As a part of the diagnosis, a medical practitioner who is experienced in treating hereditary angioedema must do a skin biopsy to find out the exact cause of allergic skin reaction.

Rising awareness regarding hereditary angioedema is expected to drive growth of the global hereditary angioedema market during the forecast period. Hereditary angioedema or also referred to as HAE has received significant attention in the recent past as government and non-government organizations across the globe are focused on increasing public awareness to improve diagnosis and enhance the treatment. For instance, in April 2019, HAE International (HAEi) organized an HAE global walk across various countries including Argentina, Australia, New Zealand, Denmark, Finland, Malta, etc. Thus, these factors are expected to drive growth of the global hereditary angioedema market during the forecast period. Moreover, the prevalence of hereditary angioedema is expected to boost the global hereditary angioedema market growth over the forecast period. According to the National Institutes of Health (NIH), hereditary angioedema is expected to affect 1 in 500,000 people in the U.S., of which 85% of cases are expected to be Type I.

However, misdiagnosis of hereditary angioedema is expected to hamper the global hereditary angioedema market growth over the forecast period. Besides, continuous research and development activities in the field of orphan drug development can present lucrative growth opportunities in the global hereditary angioedema market in the near future. Among regions, North America is expected to witness significant growth in the global hereditary angioedema market during the forecast period. This is owing to the presence of robust healthcare infrastructure and new product launches by market players across the region. Moreover, Asia Pacific is expected to register a robust growth rate over the forecast period, owing to rising patient awareness across the region.

Major companies involved in the global hereditary angioedema market are BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Pharming Group N.V., Attune Pharmaceuticals, Inc., CSL Limited, and Shire plc.

For instance, in December 2020, BioCryst Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for oral once-daily ORLADEYO for prophylaxis to prevent hereditary angioedema (HAE).